Loading...
Market
Number of new indications approved for Mitapivat by mid-2025?
5
Resolution / Starting Odds
0 • 33%
1 • 33%
2 or more • 34%
FDA and EMA announcements
Story
Agios' Mitapivat Achieves Positive Phase 3 Results for Thalassemia, 30.4% Response, Stock Up 20%
Jun 3, 2024, 11:24 AM
Agios Pharmaceuticals announced on Monday that its drug Mitapivat achieved positive results in a Phase 3 study for treating transfusion-dependent alpha- or beta-thalassemia in adults. The study, named ENERGIZE-T, met its primary endpoint and all key secondary endpoints. The response rate for Mitapivat was 30.4% compared to 12.6% for the placebo, showing significant reduction in the need for blood transfusions. Following the announcement, Agios' stock price surged by 20%, reaching a 2.5-year high.
View original story
Similar markets
More than 3 • 25%
3 • 25%
2 • 25%
1 or none • 25%
FDA approval • 25%
EMA approval • 25%
Both approvals • 25%
No approvals • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
0-5 • 20%
6-10 • 20%
11-15 • 20%
16-20 • 20%
More than 20 • 20%
None • 33%
One • 33%
Two or more • 34%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
